Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro

Asian Journal of Andrology

Volumn 16, Issue 6, 2014, Pages 864-868

  Song, Weitao ^a   Khera, Mohit ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

androgen; proliferation; prostate cancer; testosterone

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; ANDROGEN; CRYSTAL VIOLET; TESTOSTERONE;

ANDROGEN BLOOD LEVEL; ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LNCAP CELL LINE; MALE; PROSTATE CANCER; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGENS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84908470132     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.129132     Document Type: Article

References (23)

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7
2. Khera M, Grober ED, Najari B, Colen JS, Mohamed O, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009; 6: 1165-70
3. Morgentaler A. Testosterone therapy for men at risk for or with history of prostate cancer. Curr Treat Options Oncol 2006; 7: 363-9
4. Rhoden EL, Averbeck MA. Testosterone therapy and prostate carcinoma. Curr Urol Rep 2009; 10: 453-9
5. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766-71
6. Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, et al. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J Biomed Sci 2011; 18: 63
7. van Oort IM, Kok DE, Kiemeney LA, Hulsbergen-van de Kaa CA, Witjes JA. A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or "insignificant'. Urol Oncol 2009; 27: 509-13
8. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000; 163: 824-7
9. Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology 2008; 72: 1240-5
10. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173-81
11. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 2006; 68: 1263-7
12. Ribeiro M, Ruff P, Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 1997; 20: 605-8
13. Sofikerim M, Eskicorapci S, Oruc O, Ozen H. Hormonal predictors of prostate cancer. Urol Int 2007; 79: 13-8
14. Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, et al. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 2005; 174: 2178-80
15. Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol 2007; 52: 696-701
16. Morgentaler A. Destroying the myth about testosterone replacement and prostate cancer. Life Ext 2008; 12
17. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, et al. The LNCaP cell line - A new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980; 37: 115-32
18. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 1997; 3: 2493-500
19. Gillies RJ, Didier N, Denton M. Determination of cell number in monolayer cultures. Anal Biochem 1986; 159: 109-13
20. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809-18
21. Sonnenschein C, Olea N, Pasanen ME, Soto AM. Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res 1989; 49: 3474-81
22. Arnold JT, Le H, McFann KK, Blackman MR. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab 2005; 288: E573-84
23. Seruga B, Tannock IF. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol 2008; 5: 574-6